{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"}]}],"title":"Progressive Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"}]}],"title":"Stable Disease"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"5"}],"units":"Participants"}],"description":"Defined as either progressive disease or stable disease observed assessed by the Revised International Workshop Standardization Response Criteria for non-Hodgkin lymphoma.","groups":[{"description":"Patients receive Akt/ERK inhibitor ONC201 125 mg PO on day 1 of every cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"ONC201 125 mg"},{"description":"Patients receive Akt/ERK inhibitor ONC201 250 mg PO every 7 days. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"ONC201 250 mg"},{"description":"Patients receive Akt/ERK inhibitor ONC201 625 mg PO every 7 days. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.","id":"OG002","title":"ONC201 625 mg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"1 patient passed away prior to restaging in Phase 2 Arm B","reportingStatus":"POSTED","timeFrame":"Up to 63 days (first 3 courses)","title":"Number of Participants With Overall Response Rate (Phase 1 and 2)","type":"PRIMARY","unitOfMeasure":"Participants"}